"Adoptive Transfer" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Form of passive immunization where previously sensitized immunologic agents (cells or serum) are transferred to non-immune recipients. When transfer of cells is used as a therapy for the treatment of neoplasms, it is called adoptive immunotherapy (IMMUNOTHERAPY, ADOPTIVE).
| Descriptor ID |
D019264
|
| MeSH Number(s) |
E02.095.465.425.400.330.050 E05.478.550.520.050
|
| Concept/Terms |
Adoptive Cell Transfer- Adoptive Cell Transfer
- Adoptive Cell Transfers
- Cell Transfer, Adoptive
- Cell Transfers, Adoptive
|
Below are MeSH descriptors whose meaning is more general than "Adoptive Transfer".
Below are MeSH descriptors whose meaning is more specific than "Adoptive Transfer".
This graph shows the total number of publications written about "Adoptive Transfer" by people in this website by year, and whether "Adoptive Transfer" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 2 | 2 |
| 2001 | 0 | 2 | 2 |
| 2002 | 0 | 2 | 2 |
| 2003 | 1 | 1 | 2 |
| 2004 | 0 | 2 | 2 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 2 | 2 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 2 | 2 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2016 | 0 | 2 | 2 |
| 2017 | 4 | 19 | 23 |
| 2018 | 2 | 15 | 17 |
| 2019 | 4 | 4 | 8 |
| 2020 | 2 | 2 | 4 |
| 2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Adoptive Transfer" by people in Profiles.
-
Activation of mTORC1 at late endosomes misdirects T cell fate decision in older individuals. Sci Immunol. 2021 06 18; 6(60).
-
Adoptive transfer of ex vivo expanded SARS-CoV-2-specific cytotoxic lymphocytes: A viable strategy for COVID-19 immunosuppressed patients? Transpl Infect Dis. 2021 Aug; 23(4):e13602.
-
Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature. 2021 02; 590(7847):630-634.
-
Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation. J Clin Invest. 2020 12 01; 130(12):6656-6667.
-
Potency and timing of antiviral therapy as determinants of duration of SARS-CoV-2 shedding and intensity of inflammatory response. Sci Adv. 2020 11; 6(47).
-
Therapeutic Potential of B-1a Cells in COVID-19. Shock. 2020 11; 54(5):586-594.
-
T-cell responses and therapies against SARS-CoV-2 infection. Immunology. 2021 01; 162(1):30-43.
-
Flattening the COVID-19 Curve With Natural Killer Cell Based Immunotherapies. Front Immunol. 2020; 11:1512.
-
Reflection on passive immunotherapy in those who need most: some novel strategic arguments for obtaining safer therapeutic plasma or autologous antibodies from recovered COVID-19 infected patients. Br J Haematol. 2020 Jul; 190(1):e27-e29.
-
Mesenchymal stem cell therapy for acute respiratory distress syndrome: from basic to clinics. Protein Cell. 2020 10; 11(10):707-722.